Karyopharm Therapeutics (KPTI) Shares Outstanding (Diluted Average) (2020 - 2025)

Karyopharm Therapeutics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $8470.0 in Q1 2025.

• For the quarter ending Q1 2025, Shares Outstanding (Diluted Average) rose 10.0% year-over-year to $8470.0; the trailing twelve-month figure through Mar 2025 stood at $8470.0 (up 10.0% YoY), and the FY2023 full-year result was $114.2 million, up 39.51% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2025 stood at $8470.0, down from $127.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $127.1 million in Q2 2024, with the low at $7700.0 in Q1 2024.
• Historically, Shares Outstanding (Diluted Average) has averaged $80.5 million across 5 years, with a median of $79.4 million in 2022.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Diluted Average) jumped 46.29% — and 2024, when it tumbled 99.99%.
• Karyopharm Therapeutics' Shares Outstanding (Diluted Average) stood at $75.2 million in 2021, then grew by 8.84% to $81.9 million in 2022, then soared by 39.51% to $114.2 million in 2023, then climbed by 11.25% to $127.1 million in 2024, then plunged by 99.99% to $8470.0 in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $8470.0 (Q1 2025), $127.1 million (Q2 2024), and $7700.0 (Q1 2024), per Business Quant data.